Trichuris Suis Ova Therapy for Relapsing Multiple Sclerosis - a Safety Study
Trichuris Suis Ova Therapy for Relapsing Multiple Sclerosis - a Safety Study
The hypothesis of this study is that treatment with Trichuris suis ova will be safe and
 effective as an oral treatment of patients with relapsing multiple sclerosis.
Inclusion Criteria:

 -  age between 19 and 55 years

 -  relapsing course of multiple sclerosis (relapsing-remitting or secondary progressive
 MS with relapses

 -  duration of the disease of at least 1 year

 -  no disease modifying therapy or unchanged immunomodulatory therapy for the last 3
 months

 -  at least 2 documented relapses during the last 24 months with the last relapse within
 the last 12 months

 Exclusion Criteria:

 -  pregnancy or period of breastfeeding or missing adequate contraceptive protection for
 female premenopausal patients

 -  relapse in the last month prior enrolment

 -  treatment with steroids in the last 30 days

 -  previous treatment with mitoxantroneduring the last year

 -  previous treatment with cyclophosphamide or other intensive immunosuppression, total
 irradiation

 -  treatment with glatiramer acetate, azathioprine, IVIG or any other immunosuppressive
 or immunomodulatory drug apart from interferon-beta in the 6 months prior to enrolment

 -  cardiac insufficiency (NYHA III/IV), cardiomyopathy, significant cardiac dysrhythmia
 requiring treatment, instable or advanced ischemic heart disease (CCS III or IV),
 malignant hypertension

 -  diabetes mellitus and other autoimmune diseases

 -  history of renal insufficiency

 -  stay in tropical areas during the last 3 months

 -  eosinophilia in the blood (> 0,45 billion/l)

 -  concurrent systemic infections